Lille, France; Cambridge, MA; April 23, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the filing of its 2020 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission (SEC) and that its annual shareholders meeting will take place on Tuesday, June 15, 2021.

Go here to read the rest:
GENFIT: Publication of the 2020 Universal Registration Document and the 2020 Annual Report on Form 20-F; Annual Shareholders Meeting to take place on...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *